Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Retained Earnings: €667.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2TZ Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd STU:2TZ
69 GF Score
Price €2.40
GF Value €1.37
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Tianjin Pharmaceutical Da Ren Tang Group Retained Earnings?

Tianjin Pharmaceutical Da Ren Tang Group STU:2TZ 69 Retained Earnings is €667.4 Mil as of Mar. 2026. GuruFocus rates STU:2TZ with a GF Score™ of 69/100 and a GF Value™ of €1.37 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Tianjin Pharmaceutical Da Ren Tang Group's retained earnings for the quarter that ended in Mar. 2026 was €667.4 Mil.

Tianjin Pharmaceutical Da Ren Tang Group's quarterly retained earnings declined from Sep. 2025 (€813.5 Mil) to Dec. 2025 (€593.4 Mil) but then increased from Dec. 2025 (€593.4 Mil) to Mar. 2026 (€667.4 Mil).

Tianjin Pharmaceutical Da Ren Tang Group's annual retained earnings increased from Dec. 2023 (€564.0 Mil) to Dec. 2024 (€739.1 Mil) but then declined from Dec. 2024 (€739.1 Mil) to Dec. 2025 (€593.4 Mil).


Tianjin Pharmaceutical Da Ren Tang Group  (STU:2TZ) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Tianjin Pharmaceutical Da Ren Tang Group Retained Earnings Historical Data

* Premium members only.

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianjin Pharmaceutical Da Ren Tang Group Retained Earnings Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 525.43 577.33 563.96 739.14 593.36

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 766.78 794.13 813.49 593.36 667.37
STU:2TZ
69GF Score
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd STU:2TZ
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tianjin Pharmaceutical Da Ren Tang Group Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €667.4 Mil mean?
Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) has a Retained Earnings of €667.4 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors.
Is Tianjin Pharmaceutical Da Ren Tang Group's Retained Earnings too high?
Tianjin Pharmaceutical Da Ren Tang Group's current Retained Earnings is €667.4 Mil. Overall, Tianjin Pharmaceutical Da Ren Tang Group has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin Pharmaceutical Da Ren Tang Group's Retained Earnings compare to ZTS?
Tianjin Pharmaceutical Da Ren Tang Group's Retained Earnings of €667.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Tianjin Pharmaceutical Da Ren Tang Group and its competitors. Tianjin Pharmaceutical Da Ren Tang Group's current Retained Earnings is €667.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin Pharmaceutical Da Ren Tang Group stock overvalued right now?
Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.37, compared to a current price of €2.40 — trading 75.2% above its estimated fair value. The current Retained Earnings is €667.4 Mil. Tianjin Pharmaceutical Da Ren Tang Group's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ), the current Retained Earnings is €667.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianjin Pharmaceutical Da Ren Tang Group (STU:2TZ) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued. The current stock price of €2.40 is trading 75.2% above its estimated GF Value™ of €1.37. GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.

Key valuation signals for STU:2TZ:

  • Retained Earnings: €667.4 Mil
  • GF Value™: €1.37 vs. price of €2.40 (75.2% above fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the STU:2TZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tianjin Pharmaceutical Da Ren Tang Group Business Description

Other Exchanges T14:Singapore600329:China
Address No. 17 Baidi Road, Darentang Building, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
69GF Score

Get the complete analysis for STU:2TZ

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.40
Price
€1.37
GF Value